Vaxart: Clinical Trials

24 trials sponsored by Vaxart, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 18 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 118Completed 18
Phase 28Completed 5, Active not recruiting 1, Terminated 1, Withdrawn 1

Follow Vaxart: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T - Norovirus Infections
Phase 1CompletedVaxart602025-03-032026-07-27
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3 - SARS-CoV2, COVID-19
Phase 2Active not recruitingVaxart54852024-10-082026-10-09
A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants
VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets - Norovirus Infections
Phase 1CompletedVaxart762023-10-272026-04-15
A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose - Norovirus Infections
Phase 2CompletedVaxart1352023-01-262025-04-15
A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers
VXA-G1.1-NN - Norovirus Infections
Phase 1CompletedVaxart82022-01-242024-06-21
Norovirus Challenge Study
VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum - Norovirus Infections
Phase 1 / Phase 2CompletedVaxart1652021-12-272025-11-05
A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
VXA-CoV2-1.1-S, Placebo Tablets - COVID-19
Phase 2TerminatedVaxart662021-10-222025-04-13
Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines
VXA-G1.1-NN - Norovirus Infections
Phase 1 / Phase 2CompletedVaxart302021-04-302024-05-22
Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
VXA-GI.1.NN, Placebo Tablet - Norovirus Infections
Phase 1CompletedVaxart662021-04-262023-02-13
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 - Covid19
Phase 1CompletedVaxart352020-09-212024-06-21
Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines
VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets - Norovirus Infection
Phase 1CompletedVaxart862019-03-202022-09-21
Evaluation of Infectivity and Illness of Norwalk GI.1 Virus Lot 001-09NV in the Human Challenge Model
Norwalk GI.1 Virus - Norovirus Infection
Phase 1CompletedWCCT Global162018-10-032020-01-22
Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers
VXA-G1.1-NN Oral Vaccine - Norovirus Gastroenteritis
Phase 1CompletedVaxart662017-04-072018-05-30
Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults
VXA-A1.1 H1 Tablet Vaccine (small), VXA-A1.1 H1 Tablet Vaccine (large) - Seasonal Influenza Preventative Vaccine Pharmacodynamics
Phase 1CompletedVaxart82017-03-312018-05-30
A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine
VXA-A1.1, Fluzone®, Placebo Tablets - Influenza
Phase 2CompletedVaxart1792016-08-312022-10-06
Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet - Norovirus Gastroenteritis
Phase 1CompletedVaxart662016-07-292018-05-31
Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)
VXA-RSV-f Tablets (high dose), VXA Placebo Tablets, VXA-RSV-f Tablets (low dose) - Respiratory Syncytial Virus (RSV)
Phase 1CompletedVaxart662016-06-222018-08-16
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
AP611074 5% gel, AP611074 matching placebo - Condyloma
Phase 2CompletedVaxart2182016-01-012018-07-20
Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults
VXA-BYW.10 (Low Dose) Oral Vaccine, VXA-BYW.10 (High Dose) Oral Vaccine, Placebo Tablets - Seasonal Influenza B
Phase 1CompletedVaxart542015-10-202018-05-31
Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum
VXA-A1.1 - Seasonal Influenza
Phase 1CompletedVaxart372013-01-012014-12-10

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Caliciviridae Infections (9)  ·  COVID-19 (3)  ·  Influenza, Human (3)  ·  Influenza in Birds (2)  ·  Condylomata Acuminata (1)  ·  Papillomavirus Infections (1)  ·  Respiratory Tract Infections (1)  ·  Sexually Transmitted Diseases (1)  ·  Virus Diseases (1)

Interventions

Vaccines (3)  ·  BNT162 Vaccine (1)  ·  Gels (1)  ·  Influenza Vaccines (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  VXA-CoV2-1 vaccine (1)  ·  VXA-CoV2-1.1-S vaccine (1)

Countries

United States (20)  ·  Argentina (1)  ·  Chile (1)  ·  Ecuador (1)  ·  New Zealand (1)  ·  Serbia (1)  ·  South Africa (1)

Top investigators

David Liebowitz, MD, PhD (6)  ·  James Cummings, MD (6)  ·  Anna Novotney-Barry (2)  ·  Apinya Vutikullird, DO (1)  ·  Helen Paguntalan, MD (1)  ·  Laura Sterling, MD (1)  ·  Laura Sterling, MD, PhD (1)  ·  Martin Kabongo, MD, PhD (1)  ·  Mary Beth Manning, MD (1)  ·  Sean N Tucker, PhD (1)  ·  Sean Tucker, PhD (1)  ·  Walter Doll, PhD (1)

Results publications

PMID 23357198, PMID 26333337, PMID 29997294, PMID 31978354, PMID 33632249, PMID 35511920, PMID 40043138